Over 16 million Americans suffer from chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis.1 COPD makes it hard to breathe, and can also cause wheezing, coughing, and chest tightness. When COPD flares up, it can be quite scary, causing breathing to become extremely difficult. While medications can help with COPD, they do not always effectively control these flare-ups.2,3
If you have COPD and still experience flare-ups despite your medications, you may qualify for the AIRFLOW-3 Clinical Trial. The trial is evaluating Targeted Lung Denervation, a new investigational treatment which may potentially reduce the risk of COPD flare-ups through a one-time, non-surgical, outpatient procedure.
What is Targeted Lung Denervation (TLD)?
People with COPD have overactive nerves in their airways, which contribute to symptoms and flare-ups that can be mild, moderate or severe. COPD flare-ups can further damage your lungs, making it difficult to recover to your ‘normal’ symptom levels. While medications can help with COPD, they do not always control these flare-ups.2,3
The Nuvaira Lung Denervation System is a new investigational device used in a non-surgical procedure called Targeted Lung Denervation, or TLD. The procedure is designed to reduce airway nerve activity, which may potentially reduce the risk of COPD flare-ups.
The TLD procedure is performed through a standard bronchoscope – a thin flexible tube that is inserted through the mouth into the lungs. Once in place, the Nuvaira System delivers targeted radiofrequency (RF) energy to the nerves located on the outside of the airways. The procedure takes about one hour with most patients returning home the same day.
The Nuvaira System and TLD procedure is currently being offered at select US study centers through the AIRFLOW-3 Clinical Trial.
If you’re living with COPD and still experience flare-ups despite your medications, you may qualify for the AIRFLOW-3 Clinical Trial. The trial is evaluating Targeted Lung Denervation (TLD), an investigational treatment which may potentially reduce the risk of COPD flare-ups through a one-time, non-surgical, outpatient procedure.
If you qualify and choose to join the study, you will receive:
See If You Qualify
To see if you might qualify for the AIRFLOW-3 Clinical Trial, and to get connected with your local study center to learn more, please take the questionnaire below.
Common potential risks associated with the TLD procedure include, but are not limited to, worsening of COPD symptoms (shortness of breath, increased cough, COPD exacerbations), coughing up blood tinged mucous, difficulty swallowing, chest pain, upset stomach or feeling of fullness, trouble processing food, and fever.
Nuvaira® Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).
A flare-up is a worsening of COPD symptoms that require additional medications to treat and can also result in visits to the emergency room, visits to a doctor, or hospitalization.